Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. (LCTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · LCTX · as of Mar 31, 2025
Ownership Breakdown
128
Institutional Holders
▲ 3 vs Q4
$49.69M
Total Inst. Value
▼ $4.15M vs Q4
249.30M
Shares Outstanding
freeFloat 94.88%
109.35M
13F Shares Held
▲ 2.23M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
LCTX largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BROADWOOD CAPITAL INC biological products, (no diagnostic substances) | 49.56M | 21.92% | 21.92% | $22.38B | May 15, 2025 | ▲ 7.89M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 11.45M | 5.07% | 5.07% | $5.17B | May 2, 2025 | ▲ 1.36M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 8.92M | 3.95% | 3.95% | $4.03B | May 9, 2025 | ▲ 286.1K |
DEFENDER CAPITAL, LLC. biological products, (no diagnostic substances) | 6.31M | 2.79% | 2.79% | $3.16B | Apr 28, 2025 | ▲ 347.5K |
RAFFLES ASSOCIATES LP biological products, (no diagnostic substances) | 5.64M | 2.50% | 2.50% | $2.55B | May 15, 2025 | ▲ 150.0K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 4.49M | 1.98% | 1.98% | $2.03B | May 13, 2025 | ▲ 795.1K |
COMERICA BANK biological products, (no diagnostic substances) | 3.00M | 1.33% | 1.33% | $1.35B | May 14, 2025 | ▲ 2.20M |
STATE STREET CORP biological products, (no diagnostic substances) | 2.65M | 1.17% | 1.17% | $1.20B | May 15, 2025 | ▼ 24.3K |
DAFNA CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.51M | 1.11% | 1.11% | $1.13B | May 15, 2025 | — held |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 2.29M | 1.01% | 1.01% | $1.03B | May 14, 2025 | ▲ 8.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
27
Increased
+15.92M shares5
New Positions
first time holders11
Decreased
−1.61M shares0
Sold Out
fully exitedNet shares change (top 50)
+14.32M
+15.92M / −1.61M
Net new holders
+21
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
LCTX insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
4
Sell transactions
1.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Culley Brian M President and CEO | Mar 12, 2026 | Purchase | 15,000 | $1.63 | $24.4K | 255.5K | Form 4 ↗ |
Culley Brian M President and CEO | Mar 5, 2026 | Award | 3,250,000 | $1.84 | $5.98M | 3.25M | Form 4 ↗ |
Howe Jill Ann Chief Financial Officer | Mar 5, 2026 | Award | 1,050,000 | $1.84 | $1.93M | 1.05M | Form 4 ↗ |
Samuel George A. III General Counsel and Secretary | Mar 5, 2026 | Award | 900,000 | $1.84 | $1.66M | 900.0K | Form 4 ↗ |
Culley Brian M President and CEO | Feb 11, 2026 | Tax Withhold | 12,869 | $1.80 | $23.2K | 240.5K | Form 4 ↗ |
Samuel George A. III General Counsel and Secretary | Feb 11, 2026 | Tax Withhold | 2,502 | $1.80 | $4.5K | 31.1K | Form 4 ↗ |
Culley Brian M President and CEO | Dec 19, 2025 | Award | 8,925 | — | — | 222.5K | Form 4 ↗ |
Culley Brian M President and CEO | Dec 19, 2025 | Tax Withhold | 334 | $1.68 | $561.12 | 222.1K | Form 4 ↗ |
Samuel George A. III General Counsel and Secretary | Dec 19, 2025 | Award | 1,735 | — | — | 27.6K | Form 4 ↗ |
Samuel George A. III General Counsel and Secretary | Dec 19, 2025 | Tax Withhold | 65 | $1.68 | $109.2 | 27.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Lineage Cell Therapeutics, Inc. (LCTX) is primarily owned by institutional investors, who hold approximately 43.9% of total shares outstanding. Company insiders own approximately 5.12%, while retail and public investors account for the remaining 51.02%.
The largest institutional shareholder of Lineage Cell Therapeutics, Inc. is BROADWOOD CAPITAL INC, holding approximately 49.56 million shares — equal to 21.92% of outstanding shares — as of March 31, 2025.
A total of 128 institutional investors currently hold LCTX stock, with a combined institutional value of approximately $49,687,028 as of the most recent 13F filing period.
Frequently asked questions
LCTX ownershipLineage Cell Therapeutics, Inc. (LCTX) is primarily owned by institutional investors, who hold approximately 43.9% of shares. The largest shareholder is BROADWOOD CAPITAL INC with a 21.92% stake. Company insiders hold 5.12%. Data sourced from SEC Form 13F as of March 31, 2025.